Skip to main content

Table 1 Adrenalectomy findings in patients with hyperaldosteronism

From: Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings

Case Age Gender Medication (duration) Adrenalectomy diagnosis Spironolactone-like bodies present
1 39 M Spironolactone (6 weeks), Eplerenone (6 weeks with no treatment 3 weeks prior to surgery) Adrenal cortical adenoma (1.9 cm) Diffuse
2 59 F Spironolactone (>9 months) Adrenal cortical adenoma (0.9 cm) Diffuse
3 56 M Spironolactone (>9 months) Adrenal cortical adenoma (2.8 cm) Focal
4 61 M Spironolactone (>2 months) Nodular cortical hyperplasia Focal
5 35 M Spironolactone (5 months) Adrenal cortical adenoma (1.8 cm) None
6 60 M Spironolactone (2 months with no treatment 7 months prior to surgery) Nodular cortical hyperplasia None
7 68 M Spironolactone (>2 months) Vascular cyst None
8 60 M Eplerenone (>3 years) Adrenal cortical adenoma (1.6 cm) None
9 48 M Eplerenone (>3 months) Nodular cortical hyperplasia None
10 51 M Eplerenone (>3 years) Nodular cortical hyperplasia None
11 46 M Eplerenone (>1.5 years) Hematoma (post venus sampling) None
12 46 M Eplerenone (unknown) Lipoma None
13 43 F No treatment Adrenal cortical adenoma (2.3 cm) None
14 34 F No treatment Adrenal cortical adenoma (1.5 cm) None
15 62 M No treatment Adrenal cortical adenoma (2.3 cm) None